Larimar Therapeutics, Inc.

Informe acción NasdaqGM:LRMR

Capitalización de mercado: US$493.9m

Salud financiera de hoja de balance de Larimar Therapeutics

Salud financiera controles de criterios 6/6

Larimar Therapeutics tiene un patrimonio de los accionistas total de $198.4M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $219.0M y $20.6M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$203.71m
PatrimonioUS$198.40m
Total pasivoUS$20.62m
Activos totalesUS$219.02m

Actualizaciones recientes sobre salud financiera

Recent updates

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Oct 07

Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans

Aug 09
Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans

Larimar Therapeutics: More Data Still Needed

Jul 15

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

May 31

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Nov 13
We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

May 19
Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 02
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Laramar Therapeutics issued patent for lead pipeline candidate

Oct 20

Larimar Therapeutics prices ~$70M stock offering

Sep 14

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Sep 02
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Larimar Therapeutics GAAP EPS of -$0.47

Aug 11

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Mar 21
We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Dec 18
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Larimar under pressure as FDA puts clinical hold on CTI-1601 program

May 26

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 08
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Larimar, Avadel, Applied Therapeutics will added to Nasdaq Biotechnology Index

Dec 15

Larimar completes dosing in Friedreich’s Ataxia, provides program update

Dec 08

Larimar Therapeutics (LRMR) Investor Presentation - Slideshow

Nov 16

Larimar Therapeutics reports Q3 results

Nov 10

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($213.3M) de LRMR superan a sus pasivos a corto plazo ($16.3M).

Pasivo a largo plazo: Los activos a corto plazo de LRMR ($213.3M) superan a sus pasivos a largo plazo ($4.3M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: LRMR está libre de deudas.

Reducción de la deuda: LRMR no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 33.7%.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: LRMR tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: LRMR dispone de suficiente cash runway para 1.5 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 7.4% cada año.


Descubre empresas con salud financiera